WRAP53 and acute myeloid leukemia: In addition, the expression of hTERT, which is already indicated as a biomarker in AML, could not be correlated with the clinical characteristics analyzed in this study.<h4>Conclusion</h4>We also suggest that the low expression of WRAP53 may be associated with other mechanisms in AML, such as DNA repair, thus becoming a possible new promising molecular biomarker related to genomic stability in AML.